Co-inhibitory TIGIT and CD96 compete with co-stimulatory CD226 for their ligands CD155 and CD112 on dendritic cells (DCs) or tumor cells to suppress the anti-tumor immunity of TILs (21, 22). Here, TIGIT is linked to neoplasm.